Our Products

HLS in Canada is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties.

Product Pipeline

Clozaril Schizophrenia U.S./Canada Acquired 2015 Marketed
Absorica Acne U.S. Acquired 2016 Marketed by a third party
Vascepa CV risk reduction Canada Approved 2019 Marketed
CSAN Pronto WBC Point-of-Care Diagnostic Canada Approved 2019 Marketed
Trinomia CV risk reduction Canada In-licensed 2017 Submission under review
Perseris Schizophrenia Canada In-licensed 2019 Submission under review

For Canadian Residents, click here for commercial product information.

For U.S. Residents, click on the American flag above for more commercial product information.

Customers →

Returned Goods →

Brand names you know. Safe and effective results you trust.